



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of ) Examiner: Ronald Schwadron  
Linda Gillian Durrant et al. ) Art Unit: 1644  
Serial No. 09/623,063 )  
Filed: October 24, 2000 )  
For: "Anti-Angiogenic )  
Vaccines: Substances and )  
Methods Relating Thereto" )  
Attorney Docket No: )  
0380-P02286US0 )

1044-  
Bot-seg  
RECEIVED  
AUG 06 2003  
TECH CENTER 1600/2900

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited on August 1, 2003 with the United States Postal Service as first class mail in an envelope properly addressed to COMMISSIONER OF PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450.

08/01/03  
Date

Lynn C. Fischer  
Lynn C. Fischer

**RE-SUBMISSION OF SEQUENCE LISTING**

**UNDER 37 C.F.R. §§1.821-1.825**

In response to the Official Action dated July 2, 2003 and to comply with the requirements under 37 C.F.R. §§1.821-1.825, re-submitted herewith is a sequence listing of the amino acids presented in the above-referenced application. The sequence listing has been modified to include the organisms from which the proteins/peptides are derived. The sequence listing is being submitted in both paper copy and computer-readable form. Applicants respectfully request entry of the sequence listing into the above identified patent application. The undersigned hereby verifies that the paper copy and computer readable form of the sequence listing are identical and do not contain any

new matter.

In the event that a fee is required, the Commissioner is authorized to charge the account of the undersigned, Account No. 04-1406. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

DANN, DORFMAN, HERRELL AND SKILLMAN  
A Professional Corporation

By Patrick J. Hagan  
Patrick J. Hagan, Esq.  
PTO Registration No. 27,643

Telephone: (215) 563-4100



TECH CENTER  
AUG 06 2003  
LEVEL 1

Application No.: 09/623063

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: see enclosed communication

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**